I-Pimobendan 74150-27-9 I-Metabolism PDE inhibitor
Intlawulo:T/T, L/C
Imvelaphi yeMveliso:eTshayina
Indawo yokuthumela ngenqanawa:Beijing/Shanghai/Hangzhou
Iodolo (MOQ):1g
Ixesha lokukhokhela:3 iintsuku zokusebenza
Umthamo wemveliso:1kg/ngenyanga
Imeko yokugcina:Igcinwe kwindawo epholileyo, eyomileyo, ubushushu begumbi.
Ipakethe imathiriyeli:ibhotile, ibhotile
Ubungakanani bepakethi:1g/ibhodlela, 5/ibhotile, 10g/ibhotile, 50g/ibhotile, 500g/ibhotile
Ulwazi ngokhuseleko:UN 2811 6.1/PG 3
Intshayelelo
I-Pimobendan, liyeza lonyango lwezilwanyana.I-calcium sensitizer kunye ne-inhibitor ekhethiweyo ye-phosphodiesterase 3 (PDE3) enemiphumo emihle ye-inotropic kunye ne-vasodilator.
I-Pimobendan isetyenziswa kulawulo lokungaphumeleli kwentliziyo kwizinja, ezidla ngokubangelwa sisifo se-myxomatous mitral valve (esikwaziwa ngaphambili njenge-endocardiosis), okanye i-dilated cardiomyopathy.Uphando lubonise ukuba njenge-monotherapy, i-pimobendan yonyusa ixesha lokusinda kwaye iphucula umgangatho wobomi kwizigulana ze-canine ezine-congestive heart failure yesibini kwi-mitral valve disease xa ithelekiswa ne-benazepril, i-ACE inhibitor.
Inkcazo (USP43)
| Into | Inkcazo |
| Imbonakalo | Umgubo omhlophe okanye otyheli kancinci, ihygroscopic |
| Mp | Malunga ne-242℃ |
| Ukunyibilika | Ayinyibiliki ngokoqobo emanzini, inyibilika ngokukhululekileyo kwi-dimethylformamide, inyibilika kancinane kwi-acetone nakwi-methanil. |
| Ukuchongwa | I-infrared absorption spectrophotometry, uthelekiso lwe-pimobendan CRS. |
| Ixesha lokugcinwa kwencopho enkulu yesisombululo seSampuli sihambelana nesoMgangatho wesisombululo sesitokhwe, njengoko kufunyenwe kuvavanyo lwe-Organic Impurities. | |
| Iintsimbi ezinzima | ≤10ppm |
| I-granularity | P90 ≤ 25μ m |
| Ubungakanani besuntswana | 20-80 umnatha |
| Izinyibilikisi ezishiyekileyo | ≤ 500ppm |
| Amanzi | ≤ 1.0% |
| Isivavanyi | 98.0%~102.0% |
| Uthuthu lwesulphate | ≤ 0.10% |
| Izinto eziyeleleneyo (HPLC) | |
| ukungcola A | ≤ 0.10% |
| ukungcola B | ≤ 0.10% |
| Nakuphi na okunye ukungcola | ≤ 0.10% |
| Ukungcola ngokupheleleyo | ≤ 0.20% |
